Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024
August 22, 2024 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic...
Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
August 13, 2024 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic...
Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update
August 08, 2024 08:00 ET
|
Replimune Group Inc
Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) scheduled for September and BLA submission planned for 2H 2024Enrollment of first patient in Phase 3...
Replimune to Present at Two Upcoming Investor Conferences
July 30, 2024 16:01 ET
|
Replimune Group Inc
WOBURN, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic...
Replimune Announces $100 Million Private Placement Financing
June 13, 2024 08:30 ET
|
Replimune Group Inc
- Led by a life-sciences focused institutional investor, with participation from Redmile Group, RTW Investments, Boxer Capital and other institutional investors - - Financing follows strong primary...
Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 07, 2024 08:00 ET
|
Replimune Group Inc
WOBURN, Mass., June 07, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic...
Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
June 06, 2024 07:00 ET
|
Replimune Group Inc
Primary endpoint data shows 12-month overall response rate (ORR) of 33.6% Biologics license application (BLA) submission intended for 2H 2024; first patient expected to be enrolled in IGNYTE-3...
Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
June 03, 2024 08:00 ET
|
Replimune Group Inc
-- Investigator-assessed 12-month results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma demonstrate an overall response rate of 32.7% and duration of response...
Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024 17:00 ET
|
Replimune Group Inc
WOBURN, Mass., May 23, 2024 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic...
Replimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate Update
May 16, 2024 08:00 ET
|
Replimune Group Inc
Twelve-month primary analysis results by independent central review from the IGNYTE clinical trial of RP1 (vusolimogene oderparepvec) in anti-PD1 failed melanoma expected Q2 2024 Recent Type C CMC...